GlassScriptPhysician profile
Channa D Perera
NPI 1467458216
$17,866.72
in general payments reported to CMS, 2019-2025
55 companies · $2,834 in 2025
The $2,834 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,674 · 2020: $1,925 · 2021: $2,234 · 2022: $2,465 · 2023: $3,004 · 2024: $2,730 · 2025: $2,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,455 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,455.04 |
| Education | $113.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,301.00 | 2019-2025 | Fasenra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $2,320.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,437.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $894.89 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $796.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $793.42 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $770.24 | 2019-2025 | Gardasil 9, Capvaxive, Steglatro |
| Abbvie INC. | $763.58 | 2019-2025 | |
| Amgen INC. | $726.66 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $627.78 | 2020-2025 | |
| Exact Sciences Corporation | $509.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.33 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Otsuka America Pharmaceutical, INC. | $432.26 | 2023-2025 | Rexulti, Nuedexta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $387.57 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $355.39 | 2019-2025 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Channa Perera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.